# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
$N_{tot}$ = total number of the results
$N_{out}$ = number of the results removed before calculation
AV = assigned value
CRV = certified reference value
CVP = consensus of all participants
CVPG = consensus of the participants' groups
$U_{AV}$ = expanded uncertainty of the assigned value (k = 2)
$D_{max}$ = acceptable difference
LL = lower limit
UL = upper limit
$N_{eva}$ = number of the results assessed
$N_{suc}$ = number of successful results
$S_{rel}$ = relative success

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (22) **α-amylase** | [µkat/L] | | | | 191 | | | | | | | 0 | | | | | | | | 191 | 187 | 98 |
| **Sample A** | | 5,97 | 0,38 | 6,4 | 191 | | | | | | | 0 | | | CRV 5,89 | 0,16 | 15% | 5 | 6,78 | 191 | 188 | 98 |
| (1) Abbott | | 6,21 | 0,14 | 2,2 | 47 | 0 | | | | | | | | | | | | | | 47 | | |
| (46) Erba Lachema | | 6,25 | 0,41 | 6,5 | 7 | 0 | | | | | | | | | | | | | | 7 | | |
| (58) Beckman Coulter (AU) | | 6,01 | 0,17 | 2,8 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 5,62 | 0,11 | 1,9 | 72 | 0 | | | | | | | | | | | | | | 72 | | |
| (162) Siemens (Atellica) | | 6,38 | 0,083 | 1,3 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| Other | | | | | 8 | 0 | | | | | | | | | | | | | | 8 | | |
| | | | | | | | | | | | | | | | 2x 5, 1x 85, 1x 149, 4x 177 | | | | | | | |
| **Sample B** | | 4,84 | 0,36 | 7,3 | 191 | | | | | | | 0 | | | CRV 4,72 | 0,14 | 15% | 4,01 | 5,43 | 191 | 189 | 99 |
| (1) Abbott | | 5,16 | 0,11 | 2,2 | 47 | 0 | | | | | | | | | | | | | | 47 | | |
| (46) Erba Lachema | | 5,11 | 0,27 | 5,4 | 7 | 0 | | | | | | | | | | | | | | 7 | | |
| (58) Beckman Coulter (AU) | | 4,81 | 0,13 | 2,7 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 4,52 | 0,081 | 1,8 | 72 | 0 | | | | | | | | | | | | | | 72 | | |
| (162) Siemens (Atellica) | | 5,18 | 0,055 | 1,1 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| Other | | | | | 8 | 0 | | | | | | | | | | | | | | 8 | | |
| | | | | | | | | | | | | | | | 2x 5, 1x 85, 1x 149, 4x 177 | | | | | | | |
| (35) **α-amylase pancreatic** | [µkat/L] | | | | 69 | | | | | | | 69 | 69 | 100 | | | | | | 0 | | |
| **Sample A** | | 4,89 | 0,19 | 3,9 | 69 | | CVP 4,89 | 0,056 | 18% | 4 | 5,78 | 69 | 69 | 100 | | | | | | 0 | | |
| (1) Abbott | | 4,82 | 0,17 | 3,5 | 23 | 0 | | | | | | 23 | | | | | | | | | | |
| (46) Erba Lachema | | 4,89 | 0,24 | 4,9 | 8 | 0 | | | | | | 8 | | | | | | | | | | |
| (60) Roche | | 4,84 | 0,092 | 1,9 | 22 | 0 | | | | | | 22 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 5,47 | 0,055 | 1 | 10 | 0 | | | | | | 10 | | | | | | | | | | |
| Other | | | | | 6 | 0 | | | | | | 6 | | | | | | | | | | |
| | | | | | | | 1x 5, 3x 58, 2x 116 | | | | | | | | | | | | | | | |
| **Sample B** | | 4,14 | 0,14 | 3,4 | 69 | | CVP 4,14 | 0,041 | 18% | 3,39 | 4,89 | 69 | 69 | 100 | | | | | | 0 | | |
| (1) Abbott | | 4,1 | 0,13 | 3,1 | 23 | 0 | | | | | | 23 | | | | | | | | | | |
| (46) Erba Lachema | | 4,18 | 0,16 | 3,9 | 8 | 0 | | | | | | 8 | | | | | | | | | | |
| (60) Roche | | 4,08 | 0,075 | 1,8 | 22 | 0 | | | | | | 22 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 4,66 | 0,081 | 1,7 | 10 | 0 | | | | | | 10 | | | | | | | | | | |
| Other | | | | | 6 | 0 | | | | | | 6 | | | | | | | | | | |
| | | | | | | | 1x 5, 3x 58, 2x 116 | | | | | | | | | | | | | | | |
| (32) **γ-globulin (elfo)** | [-] | | | | 47 | | | | | | | 47 | 46 | 98 | | | | | | 0 | | |
| **Sample A** | | 0,126 | 0,02 | 16 | 47 | | CVP 0,126 | 0,007 | 30% | 0,088 | 0,164 | 47 | 46 | 98 | | | | | | 0 | | |
| (34) Sebia | | 0,12 | 0,016 | 13 | 38 | 0 | | | | | | 38 | | | | | | | | | | |
| (213) Interlab Srl | | 0,155 | 0,008 | 5,3 | 9 | 0 | | | | | | 9 | | | | | | | | | | |
| **Sample B** | | 0,124 | 0,013 | 10 | 47 | | CVP 0,124 | 0,005 | 30% | 0,086 | 0,162 | 47 | 47 | 100 | | | | | | 0 | | |
| (34) Sebia | | 0,123 | 0,013 | 11 | 38 | 0 | | | | | | 38 | | | | | | | | | | |
| (213) Interlab Srl | | 0,129 | 0,013 | 10 | 9 | 0 | | | | | | 9 | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (10) **Albumin** | [g/L] | | | | 183 | | | | | | | | 183 | 177 | 97 | | | | | | | 0 | | |
| **Sample A** | | 57,1 | 2,1 | 3,7 | 183 | | CVP | 57,1 | 0,39 | 10% | 51,3 | 62,9 | 183 | 180 | 98 | | | | | | | 0 | | |
| (1) Abbott | | 59,1 | 1,3 | 2,2 | 47 | 0 | | | | | | | 47 | | | | | | | | | | | |
| (46) Erba Lachema | | 54,6 | 2,9 | 5,3 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 56,1 | 1,3 | 2,2 | 30 | 0 | | | | | | | 30 | | | | | | | | | | | |
| (60) Roche | | 56,3 | 1,4 | 2,5 | 68 | 0 | | | | | | | 68 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 58,1 | 1,6 | 2,7 | 22 | 0 | | | | | | | 22 | | | | | | | | | | | |
| Other | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 2x 77, 1x 85, 1x 149, 3x 177, 1x 178, 2x 179 | | | | | | | | | | | | | | | | | |
| **Sample B** | | 32,3 | 1,2 | 3,9 | 183 | | CVP | 32,3 | 0,23 | 10% | 29 | 35,6 | 183 | 179 | 98 | | | | | | | 0 | | |
| (1) Abbott | | 31,6 | 0,85 | 2,7 | 47 | 0 | | | | | | | 47 | | | | | | | | | | | |
| (46) Erba Lachema | | 32,7 | 1,4 | 4,3 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 31,3 | 0,65 | 2,1 | 30 | 0 | | | | | | | 30 | | | | | | | | | | | |
| (60) Roche | | 33,3 | 0,92 | 2,8 | 68 | 0 | | | | | | | 68 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 31,9 | 1,3 | 4,2 | 22 | 0 | | | | | | | 22 | | | | | | | | | | | |
| Other | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 2x 77, 1x 85, 1x 149, 3x 177, 1x 178, 2x 179 | | | | | | | | | | | | | | | | | |
| (31) **Albumin (elpho)** | [-] | | | | 47 | | | | | | | | 47 | 41 | 87 | | | | | | | 0 | | |
| **Sample A** | | 0,64 | 0,048 | 7,4 | 47 | | CVP | 0,64 | 0,017 | 15% | 0,544 | 0,736 | 47 | 41 | 87 | | | | | | | 0 | | |
| (34) Sebia | | 0,656 | 0,032 | 4,9 | 38 | 0 | | | | | | | 38 | | | | | | | | | | | |
| (213) Interlab Srl | | 0,538 | 0,018 | 3,3 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| **Sample B** | | 0,648 | 0,03 | 4,6 | 47 | | CVP | 0,648 | 0,011 | 15% | 0,55 | 0,746 | 47 | 47 | 100 | | | | | | | 0 | | |
| (34) Sebia | | 0,657 | 0,023 | 3,5 | 38 | 0 | | | | | | | 38 | | | | | | | | | | | |
| (213) Interlab Srl | | 0,62 | 0,014 | 2,3 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| (21) **ALP** | [µkat/L] | | | | 190 | | | | | | | | 180 | 173 | 96 | | | | | | | 190 | 150 | 79 |
| **Sample A** | | 5,01 | 0,52 | 10 | 190 | | | | | | | | 180 | 176 | 98 | CRV | 4,72 | 0,13 | 18% | 3,87 | 5,57 | 190 | 169 | 89 |
| (1) Abbott | | 5,41 | 0,15 | 2,8 | 50 | 0 | CVPG | 5,41 | 0,052 | 14% | 4,65 | 6,17 | 50 | | | | | | | | | 50 | | |
| (46) Erba Lachema | | 5,1 | 0,15 | 2,9 | 5 | 0 | CVPG | 5,1 | 0,42 | 14% | 4,38 | 5,82 | 5 | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 5,48 | 0,28 | 5,2 | 30 | 0 | CVPG | 5,48 | 0,13 | 14% | 4,71 | 6,25 | 30 | | | | | | | | | 30 | | |
| (60) Roche | | 4,57 | 0,31 | 6,8 | 69 | 0 | CVPG | 4,57 | 0,092 | 14% | 3,93 | 5,21 | 69 | | | | | | | | | 69 | | |
| (162) Siemens (Atellica) | | 4,77 | 0,18 | 3,7 | 26 | 0 | CVPG | 4,77 | 0,085 | 14% | 4,1 | 5,44 | 26 | | | | | | | | | 26 | | |
| Other | | | | | 10 | 0 | | | | | | | 0 | | | | | | | | | 10 | | |
| | | | | | | | 2x 5, 1x 85, 1x 149, 2x 158, 4x 177 | | | | | | | | | 2x 5, 1x 85, 1x 149, 2x 158, 4x 177 | | | | | | | | |
| **Sample B** | | 0,739 | 0,067 | 9 | 190 | | | | | | | | 180 | 173 | 96 | CRV | 0,691 | 0,019 | 18% | 0,566 | 0,816 | 190 | 161 | 85 |
| (1) Abbott | | 0,811 | 0,039 | 4,8 | 50 | 0 | CVPG | 0,811 | 0,014 | 14% | 0,697 | 0,925 | 50 | | | | | | | | | 50 | | |
| (46) Erba Lachema | | 0,69 | 0,015 | 2,1 | 5 | 0 | CVPG | 0,69 | 0,042 | 14% | 0,593 | 0,787 | 5 | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 0,712 | 0,045 | 6,3 | 30 | 0 | CVPG | 0,712 | 0,02 | 14% | 0,612 | 0,812 | 30 | | | | | | | | | 30 | | |
| (60) Roche | | 0,706 | 0,044 | 6,2 | 69 | 0 | CVPG | 0,706 | 0,013 | 14% | 0,607 | 0,805 | 69 | | | | | | | | | 69 | | |
| (162) Siemens (Atellica) | | 0,712 | 0,041 | 5,7 | 26 | 0 | CVPG | 0,712 | 0,02 | 14% | 0,612 | 0,812 | 26 | | | | | | | | | 26 | | |
| Other | | | | | 10 | 0 | | | | | | | 0 | | | | | | | | | 10 | | |
| | | | | | | | 2x 5, 1x 85, 1x 149, 2x 158, 4x 177 | | | | | | | | | 2x 5, 1x 85, 1x 149, 2x 158, 4x 177 | | | | | | | | |
| (24) **ALT** | [µkat/L] | | | | 195 | | | | | | | | 0 | | | | | | | | | 195 | 192 | 98 |
| **Sample A** | | 1,78 | 0,1 | 5,7 | 195 | | | | | | | | 0 | | | CRV | 1,804 | 0,041 | 15% | 1,53 | 2,08 | 195 | 194 | 99 |
| (1) Abbott | | 1,84 | 0,073 | 4 | 50 | 0 | | | | | | | | | | | | | | | | 50 | | |
| (46) Erba Lachema | | 1,95 | 0,052 | 2,7 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 1,79 | 0,061 | 3,4 | 31 | 0 | | | | | | | | | | | | | | | | 31 | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (60) Roche | | 1,71 | 0,078 | 4,6 | 72 | 0 | | | | | | | | | | | | | | 72 | | |
| (162) Siemens (Atellica) | | 1,84 | 0,03 | 1,6 | 27 | 0 | | | | | | | | | | | | | | 27 | | |
| (177) Mindray | | 1,76 | 0,059 | 3,4 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| | | | | | | | | | | | | | | | 1x 85, 1x 121, 1x 149, 2x 178 | | | | | | | |
| **Sample B** | | 1,18 | 0,066 | 5,6 | 195 | | | | | | | 0 | | | CRV | 1,164 | 0,031 | 15% | 0,989 | 1,34 | 195 | 193 | 99 |
| (1) Abbott | | 1,17 | 0,053 | 4,5 | 50 | 0 | | | | | | | | | | | | | | 50 | | |
| (46) Erba Lachema | | 1,29 | 0,022 | 1,7 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 1,19 | 0,035 | 3 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 1,14 | 0,051 | 4,4 | 72 | 0 | | | | | | | | | | | | | | 72 | | |
| (162) Siemens (Atellica) | | 1,26 | 0,022 | 1,7 | 27 | 0 | | | | | | | | | | | | | | 27 | | |
| (177) Mindray | | 1,24 | 0,015 | 1,2 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| | | | | | | | | | | | | | | | 1x 85, 1x 121, 1x 149, 2x 178 | | | | | | | |
| (23) **AST** | [µkat/L] | | | | 195 | | | | | | | 0 | | | | | | | | 195 | 185 | 95 |
| **Sample A** | | 1,63 | 0,089 | 5,5 | 195 | | | | | | | 0 | | | CRV | 1,632 | 0,036 | 15% | 1,38 | 1,88 | 195 | 185 | 95 |
| (1) Abbott | | 1,71 | 0,04 | 2,3 | 50 | 0 | | | | | | | | | | | | | | 50 | | |
| (46) Erba Lachema | | 1,62 | 0,015 | 0,91 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 1,63 | 0,11 | 6,7 | 30 | 0 | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 1,58 | 0,075 | 4,8 | 73 | 0 | | | | | | | | | | | | | | 73 | | |
| (162) Siemens (Atellica) | | 1,63 | 0,057 | 3,5 | 27 | 0 | | | | | | | | | | | | | | 27 | | |
| (177) Mindray | | 1,52 | 0,1 | 6,8 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| | | | | | | | | | | | | | | | 1x 12, 1x 85, 1x 149, 2x 178 | | | | | | | |
| **Sample B** | | 2,04 | 0,069 | 3,4 | 195 | | | | | | | 0 | | | CRV | 2,017 | 0,044 | 15% | 1,71 | 2,32 | 195 | 193 | 99 |
| (1) Abbott | | 2,04 | 0,035 | 1,7 | 50 | 0 | | | | | | | | | | | | | | 50 | | |
| (46) Erba Lachema | | 2 | 0,015 | 0,74 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 2,08 | 0,08 | 3,8 | 30 | 0 | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 2 | 0,063 | 3,2 | 73 | 0 | | | | | | | | | | | | | | 73 | | |
| (162) Siemens (Atellica) | | 2,11 | 0,05 | 2,4 | 27 | 0 | | | | | | | | | | | | | | 27 | | |
| (177) Mindray | | 2,1 | 0,052 | 2,5 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| | | | | | | | | | | | | | | | 1x 12, 1x 85, 1x 149, 2x 178 | | | | | | | |
| (13) **Bilirubin total** | [µmol/L] | | | | 195 | | | | | | | 0 | | | | | | | | 195 | 192 | 98 |
| **Sample A** | | 16,9 | 1,8 | 11 | 195 | | | | | | | 0 | | | CRV | 16,49 | 0,43 | 26% | 12,2 | 20,8 | 195 | 193 | 99 |
| (1) Abbott | | 17,2 | 0,67 | 3,9 | 50 | 0 | | | | | | | | | | | | | | 50 | | |
| (46) Erba Lachema | | 16,4 | 0,67 | 4,1 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 19,5 | 0,5 | 2,6 | 29 | 0 | | | | | | | | | | | | | | 29 | | |
| (60) Roche | | 15,2 | 0,65 | 4,3 | 73 | 0 | | | | | | | | | | | | | | 73 | | |
| (162) Siemens (Atellica) | | 17,9 | 0,49 | 2,7 | 27 | 0 | | | | | | | | | | | | | | 27 | | |
| (177) Mindray | | 18 | 0,44 | 2,5 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| | | | | | | | | | | | | | | | 2x 70, 2x 77, 1x 85, 1x 149 | | | | | | | |
| **Sample B** | | 51,1 | 4,6 | 9 | 195 | | | | | | | 0 | | | CRV | 50,2 | 1,2 | 26% | 37,1 | 63,3 | 195 | 194 | 99 |
| (1) Abbott | | 53,3 | 1,3 | 2,5 | 50 | 0 | | | | | | | | | | | | | | 50 | | |
| (46) Erba Lachema | | 51,9 | 4,2 | 8 | 5 | 0 | | | | | | | | | | | | | | 5 | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (58) Beckman Coulter (AU) | | 54,6 | 1,5 | 2,7 | 29 | 0 | | | | | | | | | | | | | | 29 | | |
| (60) Roche | | 46,3 | 0,95 | 2 | 73 | 0 | | | | | | | | | | | | | | 73 | | |
| (162) Siemens (Atellica) | | 54,6 | 1,3 | 2,4 | 27 | 0 | | | | | | | | | | | | | | 27 | | |
| (177) Mindray | | 54 | 2,7 | 5 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| | | | | | | | | | | | | | | | 2x 70, 2x 77, 1x 85, 1x 149 | | | | | | | |
| (14) **Bilirubin direct** | [µmol/L] | | | | 163 | | | | | | | 152 | 146 | 96 | | | | | | 0 | | |
| **Sample A** | | 4,81 | 0,49 | 10 | 163 | | | | | | | 152 | 148 | 97 | | | | | | 0 | | |
| (1) Abbott | | 4,77 | 0,32 | 6,7 | 45 | 0 | CVPG 4,77 | 0,12 | 20% | 3,81 | 5,73 | 45 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 2,8 | 0,26 | 9,2 | 23 | 0 | CVPG 2,8 | 0,13 | 20% | 2,24 | 3,36 | 23 | | | | | | | | | | |
| (60) Roche | | 5,06 | 0,31 | 6,1 | 60 | 0 | CVPG 5,06 | 0,097 | 20% | 4,04 | 6,08 | 60 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 4,98 | 0,097 | 1,9 | 24 | 0 | CVPG 4,98 | 0,048 | 20% | 3,98 | 5,98 | 24 | | | | | | | | | | |
| Other | | | | | 11 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | | 4x 46, 2x 70, 1x 77, 4x 177 | | | | | | | | | | | | | | | |
| **Sample B** | | 11,5 | 4,4 | 39 | 163 | | | | | | | 152 | 149 | 98 | | | | | | 0 | | |
| (1) Abbott | | 7,53 | 0,47 | 6,2 | 45 | 0 | CVPG 7,53 | 0,17 | 20% | 6,02 | 9,04 | 45 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 7,73 | 0,55 | 7,1 | 23 | 0 | CVPG 7,73 | 0,28 | 20% | 6,18 | 9,28 | 23 | | | | | | | | | | |
| (60) Roche | | 13,6 | 1,1 | 7,9 | 60 | 0 | CVPG 13,6 | 0,34 | 20% | 10,8 | 16,4 | 60 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 17,4 | 0,77 | 4,4 | 24 | 0 | CVPG 17,4 | 0,39 | 20% | 13,9 | 20,9 | 24 | | | | | | | | | | |
| Other | | | | | 11 | 0 | | | | | | 0 | | | | | | | | | | |
| | | | | | | | 4x 46, 2x 70, 1x 77, 4x 177 | | | | | | | | | | | | | | | |
| (9) **Total protein** | [g/L] | | | | 184 | | | | | | | 0 | | | | | | | | 184 | 182 | 99 |
| **Sample A** | | 93,1 | 2,6 | 2,8 | 184 | | | | | | | 0 | | | CRV 94,5 | 2,2 | 9% | 85,9 | 104 | 184 | 182 | 99 |
| (1) Abbott | | 94,8 | 2 | 2,1 | 48 | 0 | | | | | | | | | | | | | | 48 | | |
| (58) Beckman Coulter (AU) | | 93,9 | 2,6 | 2,8 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 91,4 | 2 | 2,2 | 69 | 0 | | | | | | | | | | | | | | 69 | | |
| (162) Siemens (Atellica) | | 93 | 2,3 | 2,4 | 24 | 0 | | | | | | | | | | | | | | 24 | | |
| Other | | | | | 12 | 0 | | | | | | | | | | | | | | 12 | | |
| | | | | | | | | | | | | | | | 3x 46, 1x 85, 1x 149, 4x 177, 3x 179 | | | | | | | |
| **Sample B** | | 49,8 | 1,3 | 2,5 | 184 | | | | | | | 0 | | | CRV 51,1 | 1,1 | 9% | 46,5 | 55,7 | 184 | 183 | 99 |
| (1) Abbott | | 50,3 | 1,2 | 2,4 | 48 | 0 | | | | | | | | | | | | | | 48 | | |
| (58) Beckman Coulter (AU) | | 50,2 | 1,6 | 3,2 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 49,2 | 0,94 | 1,9 | 69 | 0 | | | | | | | | | | | | | | 69 | | |
| (162) Siemens (Atellica) | | 50,2 | 1,2 | 2,4 | 24 | 0 | | | | | | | | | | | | | | 24 | | |
| Other | | | | | 12 | 0 | | | | | | | | | | | | | | 12 | | |
| | | | | | | | | | | | | | | | 3x 46, 1x 85, 1x 149, 4x 177, 3x 179 | | | | | | | |
| (26) **CK** | [µkat/L] | | | | 179 | | | | | | | 0 | | | | | | | | 179 | 175 | 98 |
| **Sample A** | | 2,75 | 0,2 | 7,2 | 179 | | | | | | | 0 | | | CRV 2,87 | 0,1 | 20% | 2,29 | 3,45 | 179 | 178 | 99 |
| (1) Abbott | | 2,81 | 0,17 | 5,9 | 45 | 0 | | | | | | | | | | | | | | 45 | | |
| (46) Erba Lachema | | 2,83 | 0,2 | 7,1 | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 2,76 | 0,17 | 6,3 | 28 | 0 | | | | | | | | | | | | | | 28 | | |
| (60) Roche | | 2,72 | 0,21 | 7,7 | 68 | 0 | | | | | | | | | | | | | | 68 | | |
| (162) Siemens (Atellica) | | 2,62 | 0,21 | 7,9 | 23 | 0 | | | | | | | | | | | | | | 23 | | |
| Other | | | | | 9 | 0 | | | | | | | | | | | | | | 9 | | |
| | | | | | | | | | | | | | | | 1x 0, 2x 5, 1x 149, 4x 177, 1x 200 | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Sample B** | | 1,96 | 0,13 | 6,6 | 179 | | | | | | | 0 | | | CRV 2,068 | 0,055 | 20% | 1,65 | 2,49 | 179 | 176 | 98 |
| (1) Abbott | | 2,02 | 0,11 | 5,3 | 45 | 0 | | | | | | | | | | | | | | 45 | | |
| (46) Erba Lachema | | 2 | 0,12 | 5,9 | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 1,97 | 0,11 | 5,7 | 28 | 0 | | | | | | | | | | | | | | 28 | | |
| (60) Roche | | 1,95 | 0,12 | 6,3 | 68 | 0 | | | | | | | | | | | | | | 68 | | |
| (162) Siemens (Atellica) | | 1,83 | 0,13 | 7 | 23 | 0 | | | | | | | | | | | | | | 23 | | |
| Other | | | | | 9 | 0 | | | | | | | | | | | | | | 9 | | |
| | | | | | | | | | | | | | | | 1x 0, 2x 5, 1x 149, 4x 177, 1x 200 | | | | | | | |
| (2) **Potassium** | [mmol/L] | | | | 199 | | | | | | | 0 | | | | | | | | 199 | 196 | 98 |
| **Sample A** | | 6,66 | 0,12 | 1,8 | 199 | | | | | | | 0 | | | CRV 6,569 | 0,099 | 7% | 6,1 | 7,03 | 199 | 196 | 98 |
| (1) Abbott | | 6,64 | 0,09 | 1,4 | 53 | 0 | | | | | | | | | | | | | | 53 | | |
| (58) Beckman Coulter (AU) | | 6,51 | 0,1 | 1,5 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 6,71 | 0,095 | 1,4 | 73 | 0 | | | | | | | | | | | | | | 73 | | |
| (162) Siemens (Atellica) | | 6,68 | 0,085 | 1,3 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| Other | | | | | 16 | 0 | | | | | | | | | | | | | | 16 | | |
| | | | | | | | | | | | | | | | 1x 3, 1x 11, 2x 46, 1x 77, 1x 85, 1x 149, 3x 177, 2x 178, 4x 179 | | | | | | | |
| **Sample B** | | 3,63 | 0,07 | 1,9 | 199 | | | | | | | 0 | | | CRV 3,588 | 0,054 | 7% | 3,33 | 3,84 | 199 | 198 | 99 |
| (1) Abbott | | 3,59 | 0,057 | 1,6 | 53 | 0 | | | | | | | | | | | | | | 53 | | |
| (58) Beckman Coulter (AU) | | 3,57 | 0,044 | 1,2 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 3,67 | 0,06 | 1,6 | 73 | 0 | | | | | | | | | | | | | | 73 | | |
| (162) Siemens (Atellica) | | 3,64 | 0,047 | 1,3 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| Other | | | | | 16 | 0 | | | | | | | | | | | | | | 16 | | |
| | | | | | | | | | | | | | | | 1x 3, 1x 11, 2x 46, 1x 77, 1x 85, 1x 149, 3x 177, 2x 178, 4x 179 | | | | | | | |
| (5) **Inorganic phosphate** | [mmol/L] | | | | 181 | | | | | | | 181 | 173 | 96 | | | | | | 0 | | |
| **Sample A** | | 1,98 | 0,047 | 2,4 | 181 | | CVP 1,98 | 0,009 | 10% | 1,78 | 2,18 | 181 | 181 | 100 | | | | | | 0 | | |
| (1) Abbott | | 1,97 | 0,041 | 2,1 | 46 | 0 | | | | | | 46 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 1,99 | 0,034 | 1,7 | 29 | 0 | | | | | | 29 | | | | | | | | | | |
| (60) Roche | | 1,97 | 0,051 | 2,6 | 68 | 0 | | | | | | 68 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 2 | 0,037 | 1,9 | 24 | 0 | | | | | | 24 | | | | | | | | | | |
| Other | | | | | 14 | 0 | | | | | | 14 | | | | | | | | | | |
| | | | | | | | 1x 0, 4x 46, 2x 77, 1x 149, 4x 177, 2x 179 | | | | | | | | | | | | | | | | |
| **Sample B** | | 0,786 | 0,026 | 3,3 | 181 | | CVP 0,786 | 0,005 | 10% | 0,707 | 0,865 | 181 | 173 | 96 | | | | | | 0 | | |
| (1) Abbott | | 0,776 | 0,029 | 3,7 | 46 | 0 | | | | | | 46 | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,799 | 0,02 | 2,5 | 29 | 0 | | | | | | 29 | | | | | | | | | | |
| (60) Roche | | 0,786 | 0,021 | 2,7 | 68 | 0 | | | | | | 68 | | | | | | | | | | |
| (162) Siemens (Atellica) | | 0,793 | 0,018 | 2,3 | 24 | 0 | | | | | | 24 | | | | | | | | | | |
| Other | | | | | 14 | 0 | | | | | | 14 | | | | | | | | | | |
| | | | | | | | 1x 0, 4x 46, 2x 77, 1x 149, 4x 177, 2x 179 | | | | | | | | | | | | | | | | |
| (27) **gamma-GT** | [µkat/L] | | | | 194 | | | | | | | 0 | | | | | | | | 194 | 194 | 100 |
| **Sample A** | | 3,15 | 0,12 | 3,9 | 194 | | | | | | | 0 | | | CRV 3,184 | 0,079 | 21% | 2,51 | 3,86 | 194 | 194 | 100 |
| (1) Abbott | | 3,1 | 0,13 | 4,2 | 49 | 0 | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 3,14 | 0,14 | 4,5 | 9 | 0 | | | | | | | | | | | | | | 9 | | |
| (58) Beckman Coulter (AU) | | 3,08 | 0,082 | 2,7 | 30 | 0 | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 3,18 | 0,084 | 2,7 | 71 | 0 | | | | | | | | | | | | | | 71 | | |
| (162) Siemens (Atellica) | | 3,27 | 0,084 | 2,6 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| (177) Mindray | | 3,1 | 0,03 | 0,96 | 5 | 0 | | | | | | | | | | | | | | 5 | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | | | | | | | | Traceability | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | 2x 5, 1x 85, 1x 149 | | | | | | | |
| **Sample B** | | 0,979 | 0,039 | 4 | 194 | | | | | | | 0 | | | CRV | 1,017 | 0,025 | 21% | 0,803 | 1,24 | 194 | 194 | 100 |
| (1) Abbott | | 0,964 | 0,037 | 3,8 | 49 | 0 | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 0,955 | 0,037 | 3,9 | 9 | 0 | | | | | | | | | | | | | | 9 | | |
| (58) Beckman Coulter (AU) | | 0,954 | 0,019 | 1,9 | 30 | 0 | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 0,982 | 0,024 | 2,5 | 71 | 0 | | | | | | | | | | | | | | 71 | | |
| (162) Siemens (Atellica) | | 1,03 | 0,025 | 2,4 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| (177) Mindray | | 0,99 | 0,015 | 1,5 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | 2x 5, 1x 85, 1x 149 | | | | | | | |
| (16) **Glucose** | [mmol/L] | | | | 201 | | | | | | | 0 | | | | | | | | 201 | 199 | 99 |
| **Sample A** | | 6,14 | 0,16 | 2,7 | 201 | | | | | | | 0 | | | CRV | 6,161 | 0,063 | 8% | 5,66 | 6,66 | 201 | 199 | 99 |
| (1) Abbott | | 6,05 | 0,12 | 2 | 49 | 0 | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 6,4 | 0,2 | 3,1 | 9 | 0 | | | | | | | | | | | | | | 9 | | |
| (58) Beckman Coulter (AU) | | 6,11 | 0,15 | 2,5 | 30 | 0 | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 6,19 | 0,12 | 2 | 74 | 0 | | | | | | | | | | | | | | 74 | | |
| (162) Siemens (Atellica) | | 6,08 | 0,13 | 2,2 | 28 | 0 | | | | | | | | | | | | | | 28 | | |
| (177) Mindray | | 6,23 | 0,1 | 1,7 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| | | | | | | | | | | | | | | | 2x 5, 1x 49, 1x 75, 1x 85, 1x 149 | | | | | | | |
| **Sample B** | | 6,8 | 0,15 | 2,2 | 201 | | | | | | | 0 | | | CRV | 6,787 | 0,068 | 8% | 6,24 | 7,33 | 201 | 200 | 100 |
| (1) Abbott | | 6,71 | 0,12 | 1,7 | 49 | 0 | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 6,98 | 0,082 | 1,2 | 9 | 0 | | | | | | | | | | | | | | 9 | | |
| (58) Beckman Coulter (AU) | | 6,79 | 0,16 | 2,3 | 30 | 0 | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 6,84 | 0,12 | 1,8 | 74 | 0 | | | | | | | | | | | | | | 74 | | |
| (162) Siemens (Atellica) | | 6,75 | 0,11 | 1,6 | 28 | 0 | | | | | | | | | | | | | | 28 | | |
| (177) Mindray | | 6,93 | 0,19 | 2,8 | 5 | 0 | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| | | | | | | | | | | | | | | | 2x 5, 1x 49, 1x 75, 1x 85, 1x 149 | | | | | | | |
| (7) **Magnesium** | [mmol/L] | | | | 179 | | | | | | | 179 | 175 | 98 | | | | | | 0 | | |
| **Sample A** | | 0,987 | 0,03 | 3 | 179 | | CRV | 0,956 | 0,015 | 11% | 0,85 | 1,07 | 179 | 175 | 98 | | | | | | 0 | | |
| (1) Abbott | | 0,974 | 0,03 | 3,1 | 48 | 0 | | | | | | | 48 | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,982 | 0,023 | 2,3 | 29 | 0 | | | | | | | 29 | | | | | | | | | |
| (60) Roche | | 0,996 | 0,021 | 2,1 | 66 | 0 | | | | | | | 66 | | | | | | | | | |
| (162) Siemens (Atellica) | | 0,993 | 0,036 | 3,6 | 23 | 0 | | | | | | | 23 | | | | | | | | | |
| Other | | | | | 13 | 0 | | | | | | | 13 | | | | | | | | | |
| | | | | | | | 1x 0, 1x 46, 3x 77, 1x 85, 1x 149, 4x 177, 2x 179 | | | | | | | | | | | | | | | |
| **Sample B** | | 0,803 | 0,023 | 2,9 | 179 | | CVP | 0,803 | 0,004 | 11% | 0,714 | 0,892 | 179 | 178 | 99 | | | | | | 0 | | |
| (1) Abbott | | 0,8 | 0,027 | 3,4 | 48 | 0 | | | | | | | 48 | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,803 | 0,024 | 3 | 29 | 0 | | | | | | | 29 | | | | | | | | | |
| (60) Roche | | 0,806 | 0,017 | 2,1 | 66 | 0 | | | | | | | 66 | | | | | | | | | |
| (162) Siemens (Atellica) | | 0,802 | 0,02 | 2,4 | 23 | 0 | | | | | | | 23 | | | | | | | | | |
| Other | | | | | 13 | 0 | | | | | | | 13 | | | | | | | | | |
| | | | | | | | 1x 0, 1x 46, 3x 77, 1x 85, 1x 149, 4x 177, 2x 179 | | | | | | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (3) **Chloride** | [mmol/L] | | | | 199 | | | | | | | | 199 | 194 | 97 | | | | | | | 0 | | |
| **Sample A** | | 133 | 3,6 | 2,7 | 199 | | CVP | 133 | 0,62 | 7% | 123 | 143 | 199 | 197 | 99 | | | | | | | 0 | | |
| (1) Abbott | | 137 | 1,9 | 1,4 | 53 | 0 | | | | | | | 53 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 133 | 1,6 | 1,2 | 31 | 0 | | | | | | | 31 | | | | | | | | | | | |
| (60) Roche | | 131 | 2,4 | 1,8 | 74 | 0 | | | | | | | 74 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 133 | 1,6 | 1,2 | 26 | 0 | | | | | | | 26 | | | | | | | | | | | |
| Other | | | | | 15 | 0 | | | | | | | 15 | | | | | | | | | | | |
| | | | | | | | 1x 11, 3x 46, 1x 77, 1x 149, 3x 177, 2x 178, 4x 179 | | | | | | | | | | | | | | | | | |
| **Sample B** | | 97,5 | 3,4 | 3,5 | 199 | | CVP | 97,5 | 0,59 | 7% | 90,6 | 105 | 199 | 195 | 98 | | | | | | | 0 | | |
| (1) Abbott | | 101 | 1,4 | 1,4 | 53 | 0 | | | | | | | 53 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 97,9 | 1 | 1,1 | 31 | 0 | | | | | | | 31 | | | | | | | | | | | |
| (60) Roche | | 94,3 | 1,9 | 2 | 74 | 0 | | | | | | | 74 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 98,7 | 1,6 | 1,6 | 26 | 0 | | | | | | | 26 | | | | | | | | | | | |
| Other | | | | | 15 | 0 | | | | | | | 15 | | | | | | | | | | | |
| | | | | | | | 1x 11, 3x 46, 1x 77, 1x 149, 3x 177, 2x 178, 4x 179 | | | | | | | | | | | | | | | | | |
| (15) **Cholesterol** | [mmol/L] | | | | 183 | | | | | | | | 0 | | | | | | | | | 183 | 170 | 93 |
| **Sample A** | | 6,25 | 0,2 | 3,2 | 183 | | | | | | | | 0 | | | CRV | 6,28 | 0,21 | 9% | 5,71 | 6,85 | 183 | 182 | 99 |
| (1) Abbott | | 6,27 | 0,15 | 2,5 | 48 | 0 | | | | | | | | | | | | | | | | 48 | | |
| (46) Erba Lachema | | 6,42 | 0,24 | 3,8 | 9 | 0 | | | | | | | | | | | | | | | | 9 | | |
| (58) Beckman Coulter (AU) | | 6,47 | 0,18 | 2,8 | 30 | 0 | | | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 6,19 | 0,18 | 2,9 | 66 | 0 | | | | | | | | | | | | | | | | 66 | | |
| (162) Siemens (Atellica) | | 6,11 | 0,099 | 1,6 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| (177) Mindray | | 6,21 | 0,14 | 2,3 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | | 1x 85, 1x 149, 2x 178 | | | | | | | | |
| **Sample B** | | 3,14 | 0,095 | 3 | 183 | | | | | | | | 0 | | | CRV | 3,298 | 0,039 | 9% | 3 | 3,6 | 183 | 171 | 93 |
| (1) Abbott | | 3,16 | 0,095 | 3 | 48 | 0 | | | | | | | | | | | | | | | | 48 | | |
| (46) Erba Lachema | | 3,16 | 0,067 | 2,1 | 9 | 0 | | | | | | | | | | | | | | | | 9 | | |
| (58) Beckman Coulter (AU) | | 3,13 | 0,079 | 2,5 | 30 | 0 | | | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 3,11 | 0,082 | 2,6 | 66 | 0 | | | | | | | | | | | | | | | | 66 | | |
| (162) Siemens (Atellica) | | 3,24 | 0,057 | 1,8 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| (177) Mindray | | 3,19 | 0,089 | 2,8 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | | 1x 85, 1x 149, 2x 178 | | | | | | | | |
| (30) **Cholinesterase** | [µkat/L] | | | | 51 | | | | | | | | 51 | 51 | 100 | | | | | | | 0 | | |
| **Sample A** | | 180 | 11 | 6 | 51 | | | | | | | | 51 | 51 | 100 | | | | | | | 0 | | |
| (1) Abbott | | 183 | 7,4 | 4 | 11 | 0 | CVP | 177 | 2,9 | 12% | 155 | 199 | 11 | | | | | | | | | | | |
| (46) Erba Lachema | | 178 | 13 | 7,6 | 8 | 0 | CVP | 177 | 2,9 | 12% | 155 | 199 | 8 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 174 | 4 | 2,3 | 5 | 0 | CVP | 177 | 2,9 | 12% | 155 | 199 | 5 | | | | | | | | | | | |
| (60) Roche | | 175 | 5,2 | 3 | 17 | 0 | CVP | 177 | 2,9 | 12% | 155 | 199 | 17 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 270 | 12 | 4,5 | 7 | 0 | CVPG | 270 | 12 | 8,8% | 246 | 294 | 7 | | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | | 3 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 77, 1x 116 | | | | | | | | | | | | | | | | | |
| **Sample B** | | 98,4 | 5,6 | 5,7 | 51 | | | | | | | | 51 | 51 | 100 | | | | | | | 0 | | |
| (1) Abbott | | 101 | 3,2 | 3,1 | 11 | 0 | CVP | 96,9 | 1,5 | 12% | 85,2 | 109 | 11 | | | | | | | | | | | |
| (46) Erba Lachema | | 96,2 | 7,8 | 8,1 | 8 | 0 | CVP | 96,9 | 1,5 | 12% | 85,2 | 109 | 8 | | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (58) Beckman Coulter (AU) | | 94,6 | 2,4 | 2,5 | 5 | 0 | CVP | 96,9 | 1,5 | 12% | 85,2 | 109 | 5 | | | | | | | | | | | |
| (60) Roche | | 95,7 | 2,5 | 2,6 | 17 | 0 | CVP | 96,9 | 1,5 | 12% | 85,2 | 109 | 17 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 145 | 9,3 | 6,4 | 7 | 0 | CVPG | 145 | 9,1 | 8,8% | 132 | 158 | 7 | | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | | 3 | | | | | | | | | | | |
| | | | | | | | 1x 12, 1x 77, 1x 116 | | | | | | | | | | | | | | | | | |
| (19) **Creatinine** | [µmol/L] | | | | 195 | | | | | | | | 0 | | | | | | | | | 195 | 184 | 94 |
| **Sample A** | | 142 | 6,8 | 4,8 | 195 | | | | | | | | 0 | | | CRV | 139,9 | 1,4 | 13% | 121 | 159 | 195 | 186 | 95 |
| (1) Abbott | | 142 | 11 | 7,6 | 49 | 0 | | | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 140 | 0,74 | 0,53 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 139 | 4,8 | 3,4 | 30 | 0 | | | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 144 | 6,7 | 4,7 | 72 | 0 | | | | | | | | | | | | | | | | 72 | | |
| (162) Siemens (Atellica) | | 139 | 3,8 | 2,8 | 28 | 0 | | | | | | | | | | | | | | | | 28 | | |
| (177) Mindray | | 139 | 0,3 | 0,21 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| | | | | | | | | | | | | | | | | 3x 5, 1x 85, 1x 149, 1x 179 | | | | | | | | |
| **Sample B** | | 187 | 5,5 | 2,9 | 195 | | | | | | | | 0 | | | CRV | 184,5 | 1,8 | 13% | 160 | 209 | 195 | 192 | 98 |
| (1) Abbott | | 183 | 3,3 | 1,8 | 49 | 0 | | | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 186 | 1,9 | 1 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 188 | 4,4 | 2,3 | 30 | 0 | | | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 189 | 5,9 | 3,1 | 72 | 0 | | | | | | | | | | | | | | | | 72 | | |
| (162) Siemens (Atellica) | | 187 | 4 | 2,1 | 28 | 0 | | | | | | | | | | | | | | | | 28 | | |
| (177) Mindray | | 189 | 7,4 | 3,9 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| | | | | | | | | | | | | | | | | 3x 5, 1x 85, 1x 149, 1x 179 | | | | | | | | |
| (17) **Uric acid** | [µmol/L] | | | | 193 | | | | | | | | 0 | | | | | | | | | 193 | 193 | 100 |
| **Sample A** | | 582 | 15 | 2,6 | 193 | | | | | | | | 0 | | | CRV | 585,1 | 5,9 | 12% | 514 | 656 | 193 | 193 | 100 |
| (1) Abbott | | 581 | 8,9 | 1,5 | 49 | 0 | | | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 574 | 23 | 4 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 586 | 9,9 | 1,7 | 31 | 0 | | | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 573 | 14 | 2,4 | 71 | 0 | | | | | | | | | | | | | | | | 71 | | |
| (162) Siemens (Atellica) | | 598 | 11 | 1,9 | 27 | 0 | | | | | | | | | | | | | | | | 27 | | |
| (177) Mindray | | 614 | 18 | 2,9 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | | 2x 5, 1x 85, 1x 149 | | | | | | | | |
| **Sample B** | | 290 | 10 | 3,5 | 193 | | | | | | | | 0 | | | CRV | 288,5 | 2,9 | 12% | 253 | 324 | 193 | 193 | 100 |
| (1) Abbott | | 287 | 4,7 | 1,6 | 49 | 0 | | | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 283 | 11 | 3,7 | 6 | 0 | | | | | | | | | | | | | | | | 6 | | |
| (58) Beckman Coulter (AU) | | 301 | 5,3 | 1,8 | 31 | 0 | | | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 283 | 6,4 | 2,3 | 71 | 0 | | | | | | | | | | | | | | | | 71 | | |
| (162) Siemens (Atellica) | | 298 | 5,3 | 1,8 | 27 | 0 | | | | | | | | | | | | | | | | 27 | | |
| (177) Mindray | | 296 | 9,2 | 3,1 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | | 2x 5, 1x 85, 1x 149 | | | | | | | | |
| (12) **Lactate** | [mmol/L] | | | | 80 | | | | | | | | 80 | 78 | 98 | | | | | | | 0 | | |
| **Sample A** | | 4,57 | 0,12 | 2,6 | 80 | | CVP | 4,57 | 0,032 | 15% | 3,88 | 5,26 | 80 | 80 | 100 | | | | | | | 0 | | |
| (1) Abbott | | 4,7 | 0,067 | 1,4 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | | | | | | | | Traceability | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
| (58) Beckman Coulter (AU) | | 4,43 | 0,12 | 2,6 | 11 | 0 | | | | | | | 11 | | | | | | | | | | | |
| (60) Roche | | 4,56 | 0,068 | 1,5 | 33 | 0 | | | | | | | 33 | | | | | | | | | | | |
| (61) Radiometer | | 4,65 | 0,22 | 4,8 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 4,57 | 0,091 | 2 | 18 | 0 | | | | | | | 18 | | | | | | | | | | | |
| Other | | | | | 4 | 0 | | | | | | | 4 | | | | | | | | | | | |
| | | | | | | | 1x 12, 2x 49, 1x 178 | | | | | | | | | | | | | | | | | |
| **Sample B** | | 0,99 | 0,047 | 4,7 | 80 | | CVP | 0,99 | 0,013 | 15% | 0,841 | 1,14 | 80 | 78 | 98 | | | | | | | 0 | | |
| (1) Abbott | | 1,05 | 0,03 | 2,8 | 9 | 0 | | | | | | | 9 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,927 | 0,026 | 2,8 | 11 | 0 | | | | | | | 11 | | | | | | | | | | | |
| (60) Roche | | 0,993 | 0,017 | 1,7 | 33 | 0 | | | | | | | 33 | | | | | | | | | | | |
| (61) Radiometer | | 0,95 | 0,074 | 7,8 | 5 | 0 | | | | | | | 5 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 1,01 | 0,061 | 6,1 | 18 | 0 | | | | | | | 18 | | | | | | | | | | | |
| Other | | | | | 4 | 0 | | | | | | | 4 | | | | | | | | | | | |
| | | | | | | | 1x 12, 2x 49, 1x 178 | | | | | | | | | | | | | | | | | |
| (28) **LD** | [µkat/L] | | | | 148 | | | | | | | | 0 | | | | | | | | | 148 | 146 | 99 |
| **Sample A** | | 4,14 | 0,16 | 3,8 | 148 | | | | | | | | 0 | | | CRV | 4,299 | 0,095 | 18% | 3,52 | 5,08 | 148 | 147 | 99 |
| (1) Abbott | | 4,04 | 0,17 | 4,3 | 37 | 0 | | | | | | | | | | | | | | | | 37 | | |
| (46) Erba Lachema | | 4,28 | 0,015 | 0,35 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 4,07 | 0,14 | 3,4 | 25 | 0 | | | | | | | | | | | | | | | | 25 | | |
| (60) Roche | | 4,18 | 0,11 | 2,5 | 56 | 0 | | | | | | | | | | | | | | | | 56 | | |
| (162) Siemens (Atellica) | | 4,23 | 0,085 | 2 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | | 1x 85, 2x 177, 1x 178 | | | | | | | | |
| **Sample B** | | 1,87 | 0,083 | 4,4 | 148 | | | | | | | | 0 | | | CRV | 1,976 | 0,046 | 18% | 1,62 | 2,34 | 148 | 147 | 99 |
| (1) Abbott | | 1,86 | 0,11 | 6 | 37 | 0 | | | | | | | | | | | | | | | | 37 | | |
| (46) Erba Lachema | | 1,9 | 0,022 | 1,2 | 5 | 0 | | | | | | | | | | | | | | | | 5 | | |
| (58) Beckman Coulter (AU) | | 1,8 | 0,075 | 4,1 | 25 | 0 | | | | | | | | | | | | | | | | 25 | | |
| (60) Roche | | 1,89 | 0,069 | 3,7 | 56 | 0 | | | | | | | | | | | | | | | | 56 | | |
| (162) Siemens (Atellica) | | 1,91 | 0,043 | 2,3 | 21 | 0 | | | | | | | | | | | | | | | | 21 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | | 1x 85, 2x 177, 1x 178 | | | | | | | | |
| (29) **Lipase** | [µkat/L] | | | | 107 | | | | | | | | 102 | 99 | 97 | | | | | | | 0 | | |
| **Sample A** | | 2,86 | 0,27 | 9,5 | 107 | | | | | | | | 102 | 102 | 100 | | | | | | | 0 | | |
| (1) Abbott | | 2,7 | 0,15 | 5,6 | 22 | 0 | CVPG | 2,7 | 0,079 | 18% | 2,21 | 3,19 | 22 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 2,6 | 0,075 | 2,9 | 17 | 0 | CVPG | 2,6 | 0,045 | 18% | 2,13 | 3,07 | 17 | | | | | | | | | | | |
| (60) Roche | | 2,91 | 0,19 | 6,6 | 45 | 0 | CVPG | 2,91 | 0,07 | 18% | 2,38 | 3,44 | 45 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 3,19 | 0,072 | 2,3 | 18 | 0 | CVPG | 3,19 | 0,042 | 18% | 2,61 | 3,77 | 18 | | | | | | | | | | | |
| Other | | | | | 5 | 0 | | | | | | | 0 | | | | | | | | | | | |
| | | | | | | | 1x 46, 2x 177, 1x 178, 1x 179 | | | | | | | | | | | | | | | | | |
| **Sample B** | | 0,497 | 0,048 | 9,6 | 107 | | | | | | | | 102 | 99 | 97 | | | | | | | 0 | | |
| (1) Abbott | | 0,441 | 0,056 | 13 | 22 | 0 | CVPG | 0,441 | 0,029 | 18% | 0,361 | 0,521 | 22 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 0,466 | 0,025 | 5,3 | 17 | 0 | CVPG | 0,466 | 0,015 | 18% | 0,382 | 0,55 | 17 | | | | | | | | | | | |
| (60) Roche | | 0,506 | 0,018 | 3,5 | 45 | 0 | CVPG | 0,506 | 0,007 | 18% | 0,414 | 0,598 | 45 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 0,542 | 0,028 | 5,2 | 18 | 0 | CVPG | 0,542 | 0,016 | 18% | 0,444 | 0,64 | 18 | | | | | | | | | | | |
| Other | | | | | 5 | 0 | | | | | | | 0 | | | | | | | | | | | |
| | | | | | | | 1x 46, 2x 177, 1x 178, 1x 179 | | | | | | | | | | | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (8) **Lithium** | [mmol/L] | | | | 23 | | | | | | | 0 | | | | | | | | 23 | 20 | 87 |
| **Sample A** | | 0,889 | 0,055 | 6,2 | 23 | | | | | | | 0 | | | CRV 0,918 | 0,014 | 12% | 0,807 | 1,03 | 23 | 21 | 91 |
| (60) Roche | | 0,92 | 0,03 | 3,2 | 7 | 0 | | | | | | | | | | | | | | 7 | | |
| Other | | | | | 16 | 0 | | | | | | | | | | | | | | 16 | | |
| | | | | | | | | | | | | | | | 2x 0, 3x 1, 1x 46, 1x 58, 1x 116, 1x 149, 4x 162, 1x 166, 1x 179, 1x 998 | | | | | | | |
| **Sample B** | | 0,638 | 0,042 | 6,6 | 23 | | | | | | | 0 | | | CRV 0,641 | 0,01 | 12% | 0,564 | 0,718 | 23 | 21 | 91 |
| (60) Roche | | 0,645 | 0,037 | 5,8 | 7 | 0 | | | | | | | | | | | | | | 7 | | |
| Other | | | | | 16 | 0 | | | | | | | | | | | | | | 16 | | |
| | | | | | | | | | | | | | | | 2x 0, 3x 1, 1x 46, 1x 58, 1x 116, 1x 149, 4x 162, 1x 166, 1x 179, 1x 998 | | | | | | | |
| (18) **Urea** | [mmol/L] | | | | 197 | | | | | | | 0 | | | | | | | | 197 | 196 | 99 |
| **Sample A** | | 9,4 | 0,34 | 3,6 | 197 | | | | | | | 0 | | | CRV 9,492 | 0,095 | 15% | 8,06 | 11 | 197 | 196 | 99 |
| (1) Abbott | | 9,59 | 0,39 | 4,1 | 49 | 0 | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 9,36 | 0,22 | 2,3 | 8 | 0 | | | | | | | | | | | | | | 8 | | |
| (58) Beckman Coulter (AU) | | 9,42 | 0,3 | 3,1 | 30 | 0 | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 9,24 | 0,28 | 3 | 72 | 0 | | | | | | | | | | | | | | 72 | | |
| (162) Siemens (Atellica) | | 9,47 | 0,26 | 2,8 | 28 | 0 | | | | | | | | | | | | | | 28 | | |
| (177) Mindray | | 9,5 | 0,15 | 1,6 | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | 2x 5, 1x 85, 1x 149 | | | | | | | |
| **Sample B** | | 5,05 | 0,23 | 4,6 | 197 | | | | | | | 0 | | | CRV 5,035 | 0,05 | 15% | 4,27 | 5,8 | 197 | 196 | 99 |
| (1) Abbott | | 5,14 | 0,29 | 5,6 | 49 | 0 | | | | | | | | | | | | | | 49 | | |
| (46) Erba Lachema | | 5,05 | 0,23 | 4,6 | 8 | 0 | | | | | | | | | | | | | | 8 | | |
| (58) Beckman Coulter (AU) | | 5,08 | 0,18 | 3,5 | 30 | 0 | | | | | | | | | | | | | | 30 | | |
| (60) Roche | | 4,93 | 0,15 | 3 | 72 | 0 | | | | | | | | | | | | | | 72 | | |
| (162) Siemens (Atellica) | | 5,2 | 0,2 | 3,8 | 28 | 0 | | | | | | | | | | | | | | 28 | | |
| (177) Mindray | | 5,1 | 0,3 | 5,8 | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | 2x 5, 1x 85, 1x 149 | | | | | | | |
| (11) **Osmolality** | [mmol/kg] | | | | 70 | | | | | | | 70 | 70 | 100 | | | | | | 0 | | |
| **Sample A** | | 327 | 6,1 | 1,9 | 70 | | CVP 327 | 1,8 | 5% | 310 | 344 | 70 | 70 | 100 | | | | | | 0 | | |
| (119) Advanced Instruments | | 329 | 3,1 | 0,95 | 31 | 0 | | | | | | 31 | | | | | | | | | | |
| (150) Arkray | | 321 | 4,9 | 1,5 | 21 | 0 | | | | | | 21 | | | | | | | | | | |
| (151) Fiske Associates | | 332 | 5,2 | 1,6 | 9 | 0 | | | | | | 9 | | | | | | | | | | |
| (212) GONOTEC GmbH | | 330 | 4,4 | 1,3 | 6 | 0 | | | | | | 6 | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | 3 | | | | | | | | | | |
| | | | | | | | 1x 77, 1x 162, 1x 176 | | | | | | | | | | | | | | | |
| **Sample B** | | 240 | 3,5 | 1,5 | 70 | | CVP 240 | 1 | 5% | 228 | 252 | 70 | 70 | 100 | | | | | | 0 | | |
| (119) Advanced Instruments | | 240 | 2,7 | 1,1 | 31 | 0 | | | | | | 31 | | | | | | | | | | |
| (150) Arkray | | 239 | 3,6 | 1,5 | 21 | 0 | | | | | | 21 | | | | | | | | | | |
| (151) Fiske Associates | | 242 | 0,74 | 0,31 | 9 | 0 | | | | | | 9 | | | | | | | | | | |
| (212) GONOTEC GmbH | | 244 | 5,2 | 2,1 | 6 | 0 | | | | | | 6 | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | 3 | | | | | | | | | | |
| | | | | | | | 1x 77, 1x 162, 1x 176 | | | | | | | | | | | | | | | |
| (1) **Sodium** | [mmol/L] | | | | 198 | | | | | | | 0 | | | | | | | | 198 | 195 | 98 |
| **Sample A** | | 150 | 2,3 | 1,5 | 198 | | | | | | | 0 | | | CRV 150,1 | 2,3 | 5% | 142 | 158 | 198 | 195 | 98 |
| (1) Abbott | | 150 | 1,8 | 1,2 | 53 | 0 | | | | | | | | | | | | | | 53 | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (58) Beckman Coulter (AU) | | 147 | 1,8 | 1,2 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 150 | 1,8 | 1,2 | 74 | 0 | | | | | | | | | | | | | | 74 | | |
| (162) Siemens (Atellica) | | 151 | 1,9 | 1,3 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| Other | | | | | 14 | 0 | | | | | | | | | | | | | | 14 | | |
| | | | | | | | | | | | | | | | 1x 11, 2x 46, 1x 77, 1x 149, 3x 177, 2x 178, 4x 179 | | | | | | | |
| **Sample B** | | 113 | 2 | 1,8 | 198 | | | | | | | 0 | | | CRV | 112,2 | 1,9 | 5% | 106 | 118 | 198 | 197 | 99 |
| (1) Abbott | | 112 | 1,6 | 1,4 | 53 | 0 | | | | | | | | | | | | | | 53 | | |
| (58) Beckman Coulter (AU) | | 112 | 1,4 | 1,2 | 31 | 0 | | | | | | | | | | | | | | 31 | | |
| (60) Roche | | 113 | 1,5 | 1,3 | 74 | 0 | | | | | | | | | | | | | | 74 | | |
| (162) Siemens (Atellica) | | 116 | 1,5 | 1,3 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| Other | | | | | 14 | 0 | | | | | | | | | | | | | | 14 | | |
| | | | | | | | | | | | | | | | 1x 11, 2x 46, 1x 77, 1x 149, 3x 177, 2x 178, 4x 179 | | | | | | | |
| (20) **Triacylglycerols** | [mmol/L] | | | | 183 | | | | | | | 0 | | | | | | | | 183 | 181 | 99 |
| **Sample A** | | 1,56 | 0,053 | 3,4 | 183 | | | | | | | 0 | | | CRV | 1,535 | 0,015 | 18% | 1,25 | 1,82 | 183 | 183 | 100 |
| (1) Abbott | | 1,54 | 0,034 | 2,2 | 48 | 0 | | | | | | | | | | | | | | 48 | | |
| (46) Erba Lachema | | 1,52 | 0,081 | 5,3 | 11 | 0 | | | | | | | | | | | | | | 11 | | |
| (58) Beckman Coulter (AU) | | 1,53 | 0,031 | 2 | 27 | 0 | | | | | | | | | | | | | | 27 | | |
| (60) Roche | | 1,59 | 0,038 | 2,4 | 66 | 0 | | | | | | | | | | | | | | 66 | | |
| (162) Siemens (Atellica) | | 1,6 | 0,064 | 4 | 21 | 0 | | | | | | | | | | | | | | 21 | | |
| (177) Mindray | | 1,57 | 0,022 | 1,4 | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | 1x 85, 1x 149, 2x 178 | | | | | | | |
| **Sample B** | | 1,06 | 0,072 | 6,7 | 183 | | | | | | | 0 | | | CRV | 1,023 | 0,013 | 18% | 0,838 | 1,21 | 183 | 181 | 99 |
| (1) Abbott | | 0,987 | 0,023 | 2,3 | 48 | 0 | | | | | | | | | | | | | | 48 | | |
| (46) Erba Lachema | | 1,06 | 0,064 | 6 | 11 | 0 | | | | | | | | | | | | | | 11 | | |
| (58) Beckman Coulter (AU) | | 1,03 | 0,022 | 2,2 | 27 | 0 | | | | | | | | | | | | | | 27 | | |
| (60) Roche | | 1,11 | 0,027 | 2,4 | 66 | 0 | | | | | | | | | | | | | | 66 | | |
| (162) Siemens (Atellica) | | 1,13 | 0,058 | 5,2 | 21 | 0 | | | | | | | | | | | | | | 21 | | |
| (177) Mindray | | 1,03 | 0,015 | 1,4 | 6 | 0 | | | | | | | | | | | | | | 6 | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | 4 | | |
| | | | | | | | | | | | | | | | 1x 85, 1x 149, 2x 178 | | | | | | | |
| (4) **Calcium** | [mmol/L] | | | | 188 | | | | | | | 0 | | | | | | | | 188 | 185 | 98 |
| **Sample A** | | 2,83 | 0,069 | 2,4 | 188 | | | | | | | 0 | | | CRV | 2,826 | 0,042 | 8% | 2,59 | 3,06 | 188 | 187 | 99 |
| (1) Abbott | | 2,78 | 0,065 | 2,3 | 48 | 0 | | | | | | | | | | | | | | 48 | | |
| (58) Beckman Coulter (AU) | | 2,85 | 0,056 | 2 | 29 | 0 | | | | | | | | | | | | | | 29 | | |
| (60) Roche | | 2,83 | 0,055 | 1,9 | 69 | 0 | | | | | | | | | | | | | | 69 | | |
| (162) Siemens (Atellica) | | 2,87 | 0,067 | 2,3 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| Other | | | | | 16 | 0 | | | | | | | | | | | | | | 16 | | |
| | | | | | | | | | | | | | | | 1x 0, 1x 12, 4x 46, 2x 77, 1x 85, 1x 149, 4x 177, 2x 179 | | | | | | | |
| **Sample B** | | 1,95 | 0,051 | 2,6 | 188 | | | | | | | 0 | | | CRV | 1,929 | 0,031 | 8% | 1,77 | 2,09 | 188 | 186 | 99 |
| (1) Abbott | | 1,91 | 0,059 | 3,1 | 48 | 0 | | | | | | | | | | | | | | 48 | | |
| (58) Beckman Coulter (AU) | | 1,96 | 0,029 | 1,5 | 29 | 0 | | | | | | | | | | | | | | 29 | | |
| (60) Roche | | 1,96 | 0,036 | 1,8 | 69 | 0 | | | | | | | | | | | | | | 69 | | |
| (162) Siemens (Atellica) | | 1,99 | 0,05 | 2,5 | 26 | 0 | | | | | | | | | | | | | | 26 | | |
| Other | | | | | 16 | 0 | | | | | | | | | | | | | | 16 | | |
| | | | | | | | | | | | | | | | 1x 0, 1x 12, 4x 46, 2x 77, 1x 85, 1x 149, 4x 177, 2x 179 | | | | | | | |

# Summary statistics - quantitative results

## EQA round: AKS1/26 - Basic Clinical Chemistry - Serum

Deadline: 23.1.2026

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

| Test / Sample / Group | [unit] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Comparability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Traceability | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (36) **Calcium ionised** | [mmol/L] | | | | 44 | | | | | | | | 44 | 42 | 95 | | | | | | | 0 | | |
| **Sample A** | | 1,67 | 0,047 | 2,8 | 44 | | CVP | 1,67 | 0,017 | 10% | 1,5 | 1,84 | 44 | 42 | 95 | | | | | | | 0 | | |
| (60) Roche | | 1,68 | 0,074 | 4,4 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| (61) Radiometer | | 1,67 | 0,033 | 1,9 | 26 | 0 | | | | | | | 26 | | | | | | | | | | | |
| Other | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 2x 0, 1x 38, 1x 46, 3x 53, 3x 179 | | | | | | | | | | | | | | | | | | |
| **Sample B** | | 1,39 | 0,038 | 2,7 | 44 | | CVP | 1,39 | 0,014 | 10% | 1,25 | 1,53 | 44 | 42 | 95 | | | | | | | 0 | | |
| (60) Roche | | 1,38 | 0,034 | 2,5 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| (61) Radiometer | | 1,41 | 0,035 | 2,5 | 26 | 0 | | | | | | | 26 | | | | | | | | | | | |
| Other | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 2x 0, 1x 38, 1x 46, 3x 53, 3x 179 | | | | | | | | | | | | | | | | | | |
| (6) **Iron** | [µmol/L] | | | | 163 | | | | | | | | 163 | 162 | 99 | | | | | | | 0 | | |
| **Sample A** | | 37,9 | 1,1 | 2,9 | 163 | | CVP | 37,9 | 0,21 | 15% | 32,2 | 43,6 | 163 | 162 | 99 | | | | | | | 0 | | |
| (1) Abbott | | 38,8 | 0,76 | 1,9 | 44 | 0 | | | | | | | 44 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 37,2 | 0,95 | 2,6 | 25 | 0 | | | | | | | 25 | | | | | | | | | | | |
| (60) Roche | | 37,8 | 0,92 | 2,4 | 63 | 0 | | | | | | | 63 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 37,6 | 0,85 | 2,3 | 21 | 0 | | | | | | | 21 | | | | | | | | | | | |
| Other | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 2x 46, 1x 77, 1x 85, 1x 116, 3x 177, 2x 179 | | | | | | | | | | | | | | | | | | |
| **Sample B** | | 18,9 | 0,58 | 3,1 | 163 | | CVP | 18,9 | 0,11 | 15% | 16 | 21,8 | 163 | 162 | 99 | | | | | | | 0 | | |
| (1) Abbott | | 19,1 | 0,5 | 2,6 | 44 | 0 | | | | | | | 44 | | | | | | | | | | | |
| (58) Beckman Coulter (AU) | | 18,3 | 0,53 | 2,9 | 25 | 0 | | | | | | | 25 | | | | | | | | | | | |
| (60) Roche | | 18,9 | 0,53 | 2,8 | 63 | 0 | | | | | | | 63 | | | | | | | | | | | |
| (162) Siemens (Atellica) | | 19 | 0,48 | 2,6 | 21 | 0 | | | | | | | 21 | | | | | | | | | | | |
| Other | | | | | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| | | | | | | | 2x 46, 1x 77, 1x 85, 1x 116, 3x 177, 2x 179 | | | | | | | | | | | | | | | | | | |